Kwong Kwok Wong

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Poor survival with wild-type TP53 ovarian cancer?
    Kwong Kwok Wong
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 130:565-9. 2013
  2. pmc PAX2 Expression in Ovarian Cancer
    Huijuan Song
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Mol Sci 14:6090-105. 2013
  3. pmc The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary
    Kwong Kwok Wong
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    Dis Markers 23:377-87. 2007
  4. ncbi Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis
    Kwong Kwok Wong
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Gynecol Pathol 26:404-9. 2007
  5. ncbi Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway
    Kwong Kwok Wong
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, TX 77030, USA
    Recent Pat Anticancer Drug Discov 4:28-35. 2009
  6. ncbi Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array
    Kwong Kwok Wong
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 66:11172-8. 2006
  7. pmc BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas
    Kwong Kwok Wong
    Departments of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Pathol 177:1611-7. 2010
  8. pmc Insulin-like growth factor: current concepts and new developments in cancer therapy
    Erin R King
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Unit 1362, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Recent Pat Anticancer Drug Discov 7:14-30. 2012
  9. pmc Created Gli-1 duplex short-RNA (i-Gli-RNA) eliminates CD44 Hi progenitors of taxol-resistant ovarian cancer cells
    Takashi Mine
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncol Rep 23:1537-43. 2010
  10. pmc PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas
    Celestine S Tung
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mod Pathol 22:1243-50. 2009

Research Grants

Collaborators

Detail Information

Publications36

  1. pmc Poor survival with wild-type TP53 ovarian cancer?
    Kwong Kwok Wong
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 130:565-9. 2013
    ..The objective of this study is to investigate whether wild-type TP53 status in high-grade serous ovarian carcinoma is associated with poorer survival...
  2. pmc PAX2 Expression in Ovarian Cancer
    Huijuan Song
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Mol Sci 14:6090-105. 2013
    ..In summary, PAX2 could have both oncogenic and tumor suppression functions, which might depend on the genetic content of the ovarian cancer cells. Further investigation of PAX2 in tumor suppression and mortality is warranty...
  3. pmc The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary
    Kwong Kwok Wong
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    Dis Markers 23:377-87. 2007
    ..This review summarizes the current clinical, genetic, and genomic evidence for the existence of a continuum comprising both LMP serous tumors and low-grade serous ovarian carcinomas...
  4. ncbi Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis
    Kwong Kwok Wong
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Gynecol Pathol 26:404-9. 2007
    ..These differences may lead to the development of different therapeutic strategies for women with either the low-grade or the high-grade form of OSC...
  5. ncbi Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway
    Kwong Kwok Wong
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, TX 77030, USA
    Recent Pat Anticancer Drug Discov 4:28-35. 2009
    ..In this review, we will discuss new patents or patent applications related to inhibitors of the Ras/Raf/MEK/ERK pathway...
  6. ncbi Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array
    Kwong Kwok Wong
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 66:11172-8. 2006
    ..Our results indicate that, in some pediatric glioblastoma multiforme, one allele each of EGFR and PDGFRalpha was lost but the remaining allele was amplified. This may represent a new molecular mechanism underlying tumor progression...
  7. pmc BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas
    Kwong Kwok Wong
    Departments of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Pathol 177:1611-7. 2010
    ..In addition, advanced-stage, low-grade carcinoma patients with BRAF or KRAS mutation have a better apparent clinical outcome. However, further investigation is needed...
  8. pmc Insulin-like growth factor: current concepts and new developments in cancer therapy
    Erin R King
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Unit 1362, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Recent Pat Anticancer Drug Discov 7:14-30. 2012
    ..We review the important preliminary results from clinical trials with these compounds and conclude with a discussion about future therapeutic efforts...
  9. pmc Created Gli-1 duplex short-RNA (i-Gli-RNA) eliminates CD44 Hi progenitors of taxol-resistant ovarian cancer cells
    Takashi Mine
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncol Rep 23:1537-43. 2010
    ..Targeting Notch-1 through its enhancer Gl-1, should be significant for novel treatments to eliminate taxol-resistant cancer stem cells (CSC). i.Gli-1 RNA should be more effective if used together with Taxol...
  10. pmc PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas
    Celestine S Tung
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mod Pathol 22:1243-50. 2009
    ....
  11. ncbi KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma
    Yvonne T Tsang
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA
    J Pathol 231:449-56. 2013
    ..In summary, KRAS mutations are very common in recurrent LGSC, while BRAF mutations are rare. The findings indicate that recurrent LGSC can arise from proliferation of OSBT tumour cells with or without detectable KRAS mutations...
  12. pmc TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment
    Tsz Lun Yeung
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 73:5016-28. 2013
    ..These findings suggest insights to develop or refine strategies for TGF-β-targeted therapy of ovarian cancer...
  13. ncbi Amplification of MGC2177, PLAG1, PSMC6P, and LYN in a malignant mixed tumor of salivary gland detected by cDNA microarray with tyramide signal amplification
    Yvonne T M Tsang
    Texas Children s Cancer Center, Cancer Genomics Group, MC3 3320, Department of Pediatrics, Baylor College of Medicine, 6621 Fannin Street, Houston, TX 77030, USA
    Cancer Genet Cytogenet 152:124-8. 2004
    ..2 approximately q13: MGC2177, PLAG1, PSMC6P, and LYN. The amplification was further validated with real-time quantitative polymerase chain reaction...
  14. ncbi Expression analysis of juvenile pilocytic astrocytomas by oligonucleotide microarray reveals two potential subgroups
    Kwong Kwok Wong
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
    Cancer Res 65:76-84. 2005
    ..Immunostaining of myelin basic protein on paraffin sections derived from 18 incompletely resected JPAs suggests that JPA without myelin basic protein-positively stained tumor cells may have a higher tendency to progress...
  15. pmc The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma
    Erin R King
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 123:13-8. 2011
    ..To validate the overexpression of insulin-like growth factor 1 (IGF-1) and its receptor (IGF-1R) in low-grade serous ovarian carcinoma (SOC), and to investigate whether the IGF-1 pathway is a potential therapeutic target for low-grade SOC...
  16. pmc The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer
    Erin R King
    Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Am J Surg Pathol 35:904-12. 2011
    ..The progression of SBOT to LG serous ovarian carcinoma may involve the dedifferentiation of ciliated cells. AGR3 could serve as a prognostic marker for survival in patients with LG and HG serous ovarian carcinomas...
  17. ncbi Expression profiles of osteosarcoma that can predict response to chemotherapy
    Tsz Kwong Man
    Department of Pediatrics, Texas Children s Cancer Center, Houston, Texas, USA
    Cancer Res 65:8142-50. 2005
    ..Many of the predictor genes are implicated in bone development, drug resistance, and tumorigenesis...
  18. ncbi Expression of oligodendroglial differentiation markers in pilocytic astrocytomas identifies two clinical subsets and shows a significant correlation with proliferation index and progression free survival
    Hidehiro Takei
    Department of Pathology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    J Neurooncol 86:183-90. 2008
    ..In addition, we have shown the expression of 4 different ODMs in PAs, which may support the possibility that PAs arise from oligodendrocyte progenitor/precursor cells probably similar to the O2A progenitor cells in the mouse...
  19. pmc Allelic imbalance analysis by high-density single-nucleotide polymorphic allele (SNP) array with whole genome amplified DNA
    Kwong Kwok Wong
    Texas Children s Cancer Center, Cancer Genomics Group, MC3 3320, Department of Pediatrics, Baylor College of Medicine, 6621 Fannin Street, Houston, TX 77030, USA
    Nucleic Acids Res 32:e69. 2004
    ..8%. Furthermore, using the Affymetrix GeneChip Chromosome Copy Number Tool to analyze the SNP array data, we were able to detect identical chromosomal regions with gain or loss in both amplified and unamplified DNA at cytoband resolution...
  20. ncbi Mitogen stimulation activates different signaling pathways in early- and late-divided T cells as revealed by cDNA microarray analysis
    Yufeng Li
    Graduate School of Biomedical Science, UT Health Science Center at Houston, Houston, TX 77030, USA
    Int J Mol Med 18:1127-39. 2006
    ..Because most tumors are infiltrated by lymphocytes, our studies indicate a novel approach to identify 'systemic biological responses' of T cells, which could determine the design, and optimization of effective tumor vaccines...
  21. pmc RAS promotes tumorigenesis through genomic instability induced by imbalanced expression of Aurora-A and BRCA2 in midbody during cytokinesis
    Gong Yang
    Cancer Research Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China
    Int J Cancer 133:275-85. 2013
    ..Our results suggest that the imbalance in expression of Aurora-A and BRCA2 regulates RAS-induced genomic instability and tumorigenesis...
  22. ncbi Biomarker discovery in ovarian cancer
    Celestine S Tung
    University of Texas, MD Anderson Cancer Center, Department of Gynecologic Oncology, 1515 Holcombe Blvd, Unit 1362, Houston, TX 77030, USA
    Womens Health (Lond Engl) 4:27-40. 2008
    ..Here, we review the methods of biomarker discovery, address the significance and functions of newly identified ovarian cancer tumor markers, and provide further insight into the future of ovarian cancer biomarkers...
  23. pmc A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2
    Samuel C Mok
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Cell 16:521-32. 2009
    ..Increased MAGP2 expression correlated with microvessel density suggesting a proangiogenic role in vivo. Thus, MAGP2 may serve as a survival-associated target...
  24. pmc Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer
    Tarrik M Zaid
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 19:809-20. 2013
    ....
  25. pmc Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells
    Takashi Mine
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Immunol Immunother 58:1185-94. 2009
    ..Their peptides are presented alternatively. Targeting both antagonistic proteins should be useful to prevent metastases in patients whose tumors are resistant to conventional treatments...
  26. ncbi Direct orthotopic transplantation of fresh surgical specimen preserves CD133+ tumor cells in clinically relevant mouse models of medulloblastoma and glioma
    Qin Shu
    Laboratory of Molecular Neuro Oncology, Texas Children s Cancer Center, Texas Children s Hospital, 6621 Fannin St, MC 3 3320, Houston, Texas 77030, USA
    Stem Cells 26:1414-24. 2008
    ..Disclosure of potential conflicts of interest is found at the end of this article...
  27. pmc Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer
    Joseph Kwong
    Laboratory of Gynecologic Oncology, Division of Gynecology Oncology, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Neoplasia 8:268-78. 2006
    ..Therefore, our results suggested that DLEC1 suppressed the growth of ovarian cancer cells and that its downregulation was closely associated with promoter hypermethylation and histone hypoacetylation...
  28. ncbi Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas
    Michael J Birrer
    Cell and Cancer Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Clin Oncol 25:2281-7. 2007
    ..To identify markers that can predict overall survival in patients with high-grade advanced stage serous adenocarcinomas...
  29. ncbi Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns in mucinous ovarian and appendiceal carcinomas
    Colleen M Feltmate
    Department of Obstetrics, Gynecology, and Reproductive Biology, Division of Gynecologic Oncology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Cancer Res 11:7651-7. 2005
    ..The purpose of this study is to identify molecular biomarkers for mucinous ovarian adenocarcinoma and compare them with those of appendiceal origin...
  30. ncbi Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform
    Hiroshi Tsuda
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Laboratory of Gynecologic Oncology, Brigham and Women s Hospital, Dana Farber Cancer Institute, Harvard Medical School, BLI 447, 221 Longwood Avenue, Boston, MA 02115, USA
    Cancer Genet Cytogenet 155:97-107. 2004
    ..These results show the feasibility of using the cDNA array platform to identify changes in DNA and mRNA copy number simultaneously in microdissected tumor tissues...
  31. ncbi Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker
    Heather G Huddleston
    Laboratory of Gynecologic Oncology, Department of Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Gynecol Oncol 96:77-83. 2005
    ....
  32. ncbi Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses
    Hiroshi Tsuda
    Department of Obstetrics and Gynecology, Laboratory of Gynecologic Oncology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 11:6880-8. 2005
    ..Genetic changes in this group of cancer have not been thoroughly explored. Identification of these changes may provide us new therapeutic targets to treat this disease...
  33. ncbi Osteopontin as a potential diagnostic biomarker for ovarian cancer
    Jae Hoon Kim
    Laboratory of Gynecologic Oncology, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women s Hospital, Boston, MA 02115, USA
    JAMA 287:1671-9. 2002
    ..Analyses involving complementary DNA (cDNA) microarray data can be used to identify up-regulated genes in cancer cells, whose products may then be further validated as potential biomarkers...
  34. pmc Etiology and pathogenesis of epithelial ovarian cancer
    Samuel C Mok
    Department of Obstetrics, Gynecology, and Reproductive Biology, Laboratory of Gynecologic Oncology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Dis Markers 23:367-76. 2007
    ..However, the link between all these genetic changes and the etiological factors remains to be established...
  35. ncbi Biomarker discovery in epithelial ovarian cancer by genomic approaches
    Samuel C Mok
    Department of Obstetrics, Gynecology, and Reproductive Biology, Division of Gynecologic Oncology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Adv Cancer Res 96:1-22. 2007
    ..These powerful techniques hold the potential to unravel the genetic origins of ovarian cancer. Hopefully, this will translate into earlier diagnosis and better patient outcome from disease...
  36. ncbi Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer
    Jae Hoon Kim
    Department of Obstetrics, Gynecology and Reproductive Biology, Division of Gynecologic Oncology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 9:4782-91. 2003
    ..090 in 26 normal women. This investigation has shown that the Ep-CAM autoantibody was found to be associated with ovarian cancer and suggested that future research assessing its clinical usefulness would be worthwhile...

Research Grants2

  1. Prognostic Markers for Juvenile Pilocytic Astrocytomas
    Kwong Kwok Wong; Fiscal Year: 2006
    ....
  2. Prognostic Markers for Juvenile Pilocytic Astrocytomas
    Kwong Kwok Wong; Fiscal Year: 2007
    ....